The funding comes about three years after Amgen provided the school with $1.5 million for a master's degree program in human genetics and genetic counseling.
New Scientist writes that experimental cancer drug from Amgen appears effective at targeting cancers with KRAS mutations.
The partners will use Adaptive's ClonoSeq assay to assess minimal residual disease in several of Amgen's hematology drug development programs.
The UK is partnering with pharmaceutical companies to sequence and analyze DNA samples from UK Biobank participants.
The project is funded with £50 million from the UK government, £50 million from the Wellcome Trust, and £100 million from four pharmaceutical firms.
Consenting participants will have their deidentified sequence data used for research and will also have the chance to learn if they have clinically actionable results.
The partners are both "investing heavily" in the study and will have access to the data and to new technologies and interventions.
The companies will develop analytics tools and leverage the Syapse Learning Health Network in an effort to shorten the time to market for new cancer therapies.
In PNAS this week: core Pseudomonas aeruginosa genome, study of ancient Paget's disease of the bone, and more.
In Science this week: high-resolution map of human genetic recombination, and more.
GenomeWeb reports that Veritas Genetics is suspending its US operations.
A Brazilian-led team of researchers reports it has generated a sugarcane genome assembly that encompasses more than 99 percent of its genome.
Certain plasma proteins could be used to gauge a person's age and whether they are aging well, according to HealthDay News.
In Science this week: approach to measure microRNA targeting efficiency, strategy to conduct high-throughput chemical screens at single-cell resolution, and more.